Celgene Discloses Justice Dept Probe Into Drug Marketing

Wall Street Journal -- Celgene Corp. (CELG) received notice that federal prosecutors are investigating its marketing practices for top-selling blood cancer drug Revlimid. The probe relates to Celgene's promotion of Revlimid, along with a similar drug called Thalomid, "regarding off-label marketing and improper payments to physicians." In a regulatory filing Tuesday, the Summit, N.J., drug maker said it recently received a letter from the U.S. Attorney for the Central District of California about the investigation.